Opana ER Pulled from U.S. Market Last month, the U.S. Food and Drug Administration (FDA) asked Endo Pharmaceuticals to remove oxymorphone hydrochloride extended release (Opana ER) from the U.S. market due to public health consequences related to abuse. The agency has concerns that the risks presented by the treatment do not outweigh its benefits.1 On…
Romosozumab’s Future Is Uncertain Romosozumab, which has the possible U.S. brand name Evenity, is awaiting approval from the FDA.1 The treatment is an investigational, injectable biologic for treating osteoporosis. It increases bone formation and bone density, reducing a patient’s risk of fractures. The manufacturer no longer expects the FDA to approve the drug this year…
The FDA has asked the manufactures of Opana ER to remove the opioid from the U.S. market due to the public health risk of abuse…
When she was in elementary school, Sandra Pagnussat, MD, began experiencing unrelenting pain and stiffness, first in her pinky and then in her other fingers. Her pediatrician diagnosed her with polyarticular juvenile idiopathic arthritis (JIA). In high school, Sandra decided to pursue a career in medicine and began taking advanced placement classes in biology and chemistry….
Due to possible heart-related side effects, romosozumab is no longer expected to be approved this year for the treatment of osteoporosis…
WASHINGTON, D.C.—Researchers have identified nine new genetic loci linked with juvenile idiopathic arthritis (JIA), along with evidence that at least some of them likely play a functional role, such as cytokine signaling and T cell expression. The findings were presented in an abstract session at the 2016 ACR/ARHP Annual Meeting, which also included a presentation…
WASHINGTON, D.C.—Addressing a gathering of healthcare providers at the 2016 ACR/ARHP Annual Meeting concurrent session titled, Pediatric Rheumatology for the Adult Rheumatologist, part of the ACR Review Course, expert Sangeeta Sule, MD, PhD, associate professor of pediatrics specializing in rheumatology at Johns Hopkins Hospital in Baltimore, displayed a color-coded map of the U.S. on which…
An update on baricitinib, plus safety warnings on belimumab,
eszopiclone and zoledronic acid
Information on new approvals and medication safety that rheumatologists need to know
Changing treatment paradigms in the biologic era